Synagistics Limited — Board/Management Information 2023

Jun 8, 2023

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [63 x 86] intentionally omitted <==

WEALTHKING INVESTMENTS LIMITED 華 科 資 本 有 限 公 司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1140)

CHANGE IN CHAIRMAN OF THE BOARD AND COMPOSITION OF THE NOMINATION COMMITTEE

Reference is made to the announcement (the ‘‘Announcement’’) of Wealthking Investments Limited (the ‘‘Company’’) dated 31 May 2023.

The board (‘‘Board’’) of directors (‘‘Directors’’) of the Company announces that effective 8 June 2023, Dr. Liu Zhiwei ceases to be the Chairman of the Board, and the Chairman and a member of the Nomination Committee. Dr. Liu will continue to serve as an executive Director and the authorised representative of the Company.

Dr. Liu has confirmed that he had no disagreement with the Board, and there is no matter relating to his cessation as the Chairman of the Board, and the Chairman and a member of the Nomination Committee that needs to be brought to the attention of the shareholders of the Company (the ‘‘Shareholder’’) and The Stock Exchange of Hong Kong Limited (the ‘‘Stock Exchange’’).

The Board further announces that effective 8 June 2023, Dr. Wang Qin is appointed as the Chairman of the Board and the Chairman of the Nomination Committee.

The biographical details of Dr. Wang and other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the ‘‘Listing Rules’’) are set out in the Announcement.

As disclosed in the Announcement, Dr. Wang has entered into a service contract with the Company pursuant to which Dr. Wang is entitled to a director’s fee of HK$500,000 per annum. There is no change to the remuneration package of Dr. Wang as a result of his appointment as the Chairman of the Board and the Chairman of the Nomination Committee.

– 1 –

Save as disclosed above and in the Announcement, there are no other matters in relation to the appointment of Dr. Wang as the Chairman of the Board and the Chairman of the Nomination Committee that need to be brought to the attention of the Shareholders, nor is there any information that should be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

By order of the Board Wealthking Investments Limited Wang Qin Chairman

Hong Kong SAR, 8 June 2023

As at the date of this announcement, the Board comprises one executive Director, namely, Dr. Liu Zhiwei; three non-executive Directors, namely Dr. Wang Qin, Dr. Fu Weigang and Dr. Wang Shibin; and three independent non-executive Directors, namely, Mr. Chen Yuming, Mr. Yan Xiaotian and Mr. Zhao Kai.

– 2 –